ADDED
The number of outstanding ordinary shares of the registrant, par value $0.0001 per share, as of February 15, 2026 was 212,525,437 , of which 207,451,347 ordinary shares were held in the form of ADSs.
You should carefully consider these risks and uncertainties when investing in our securities.
We are early in our development efforts and only have five product candidates, aleniglipron, ACCG-2671, ANPA-0073, LTSE-2578 and ACCG-3535, in early clinical development.
The results of prior clinical studies and preclinical studies are not necessarily predictive of future results, and may not be favorable, or receive regulatory approval on a timely basis, if at all.
International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospects.
Disruptions to the operations of the FDA, the SEC, other U.S.
governmental agencies or comparable foreign regulatory authorities caused by funding shortages, leadership changes, staffing cuts or other staffing shortages, along with uncertainty regarding the potential for new initiatives, laws, regulations, policies and guidance affecting our product candidates or other aspects of our business, could materially and adversely affect our business.
We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than us.
Our most advanced product candidate to date is aleniglipron, also known as GSBR-1290, an oral small molecule selective glucagon-like-peptide-1 receptor ( GLP-1R ) agonist currently in five ongoing clinical studies for the treatment of obesity, overweight and related conditions.
Our obesity pipeline also includes multiple preclinical discovery stage small molecules targeting glucose-dependent insulinotropic polypeptide and glucagon receptors.
REMOVED
The number of outstanding ordinary shares of the registrant, par value $0.0001 per share, as of January 31, 2025 was 172,028,543 , of which 162,671,754 ordinary shares were held in the form of ADSs.
You should carefully consider these risks and uncertainties when investing in our American Depositary Shares ( ADSs ).
We are early in our development efforts and only have four product candidates, aleniglipron, ACCG-2671, ANPA-0073 and LTSE-2578, in early clinical development.
Clinical and preclinical drug development involves a lengthy and expensive process with uncertain timelines and outcomes.
We have entered into, and may in the future enter into, collaboration agreements and strategic alliances to maximize the potential of our structure-based drug discovery platform and product candidates, and we may not realize the anticipated benefits of such collaborations or alliances.
We conduct certain research and development operations through our Australian wholly-owned subsidiaries.
If we lose our ability to operate in Australia, or if any of our subsidiaries are unable to receive the research and development tax credit allowed by Australian regulations, or are required to refund any research and development tax credit previously received or reserve for such credit in our financial statements, our business and results of operations could suffer.
Our most advanced product candidate to date is aleniglipron, also known as GSBR-1290, an oral small molecule selective glucagon-like-peptide-1 receptor ( GLP-1R ) agonist currently in two Phase 2 clinical trials for the treatment of obesity, overweight and related conditions.
Our obesity pipeline also includes ACCG-2671, an oral small molecule amylin receptor agonist development candidate in investigational new drug ( IND )-enabling studies, multiple preclinical discovery stage small molecules targeting glucose-dependent insulinotropic polypeptide ( GIP ) and glucagon ( GCG ) receptors, as well as ANPA-0073, an oral small molecule agonist targeting the apelin ( APJ ) receptor in GLP-toxicology studies and Phase 2 ready.
Importantly, these programs have the potential to be developed as monotherapy as well as in fixed dose combination with our backbone therapeutics aleniglipron or ACCG-2671, as demonstrated below.